Acne Vulgaris – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Acne Vulgaris – Pipeline Review, H2 2017’, provides an overview of the Acne Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acne Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris

The report reviews pipeline therapeutics for Acne Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acne Vulgaris therapeutics and enlists all their major and minor projects

The report assesses Acne Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acne Vulgaris

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Almirall SA

Biomar Microbial Technologies

BioPharmX Inc

Blueberry Therapeutics Ltd

Braintree Laboratories Inc

Brickell Biotech Inc

Cassiopea SpA

Celtaxsys Inc

Common Pharma Inc

Cutanea Life Sciences Inc

Deltanoid Pharmaceuticals Inc

Dermira Inc

Eligo Bioscience SAS

ELORAC Inc

Ensol Biosciences Inc

Foamix Pharmaceuticals Ltd

Galderma SA

Helix BioMedix Inc

Hovione FarmaCiencia SA

Innovation Pharmaceuticals Inc

Lee's Pharmaceutical Holdings Ltd

LEO Pharma A/S

Melinta Therapeutics Inc

Novabiotics Ltd

Novan Inc

Novartis AG

Paratek Pharmaceuticals Inc

Pfizer Inc

Phagelux Inc

Phosphagenics Ltd

Photocure ASA

Promius Pharma LLC

Provectus Biopharmaceuticals Inc

Realm Therapeutics Plc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Sol-Gel Technologies Ltd

Sun Pharmaceutical Industries Ltd

Taro Pharmaceutical Industries Ltd

Thesan Pharmaceuticals Inc

Valeant Pharmaceuticals International Inc

Vyome Biosciences Pvt Ltd

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Acne Vulgaris - Overview 6

Acne Vulgaris - Therapeutics Development 7

Acne Vulgaris - Therapeutics Assessment 18

Acne Vulgaris - Companies Involved in Therapeutics Development 28

Acne Vulgaris - Drug Profiles 46

Acne Vulgaris - Dormant Projects 172

Acne Vulgaris - Discontinued Products 177

Acne Vulgaris - Product Development Milestones 178

Appendix 193

List of Tables

List of Tables

Number of Products under Development for Acne Vulgaris, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Acne Vulgaris – Pipeline by 3SBio Inc, H2 2017

Acne Vulgaris – Pipeline by Almirall SA, H2 2017

Acne Vulgaris – Pipeline by Biomar Microbial Technologies, H2 2017

Acne Vulgaris – Pipeline by BioPharmX Inc, H2 2017

Acne Vulgaris – Pipeline by Blueberry Therapeutics Ltd, H2 2017

Acne Vulgaris – Pipeline by Braintree Laboratories Inc, H2 2017

Acne Vulgaris – Pipeline by Brickell Biotech Inc, H2 2017

Acne Vulgaris – Pipeline by Cassiopea SpA, H2 2017

Acne Vulgaris – Pipeline by Celtaxsys Inc, H2 2017

Acne Vulgaris – Pipeline by Common Pharma Inc, H2 2017

Acne Vulgaris – Pipeline by Cutanea Life Sciences Inc, H2 2017

Acne Vulgaris – Pipeline by Deltanoid Pharmaceuticals Inc, H2 2017

Acne Vulgaris – Pipeline by Dermira Inc, H2 2017

Acne Vulgaris – Pipeline by Eligo Bioscience SAS, H2 2017

Acne Vulgaris – Pipeline by ELORAC Inc, H2 2017

Acne Vulgaris – Pipeline by Ensol Biosciences Inc, H2 2017

Acne Vulgaris – Pipeline by Foamix Pharmaceuticals Ltd, H2 2017

Acne Vulgaris – Pipeline by Galderma SA, H2 2017

Acne Vulgaris – Pipeline by Helix BioMedix Inc, H2 2017

Acne Vulgaris – Pipeline by Hovione FarmaCiencia SA, H2 2017

Acne Vulgaris – Pipeline by Innovation Pharmaceuticals Inc, H2 2017

Acne Vulgaris – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017

Acne Vulgaris – Pipeline by LEO Pharma A/S, H2 2017

Acne Vulgaris – Pipeline by Melinta Therapeutics Inc, H2 2017

Acne Vulgaris – Pipeline by Novabiotics Ltd, H2 2017

Acne Vulgaris – Pipeline by Novan Inc, H2 2017

Acne Vulgaris – Pipeline by Novartis AG, H2 2017

Acne Vulgaris – Pipeline by Paratek Pharmaceuticals Inc, H2 2017

Acne Vulgaris – Pipeline by Pfizer Inc, H2 2017

Acne Vulgaris – Pipeline by Phagelux Inc, H2 2017

Acne Vulgaris – Pipeline by Phosphagenics Ltd, H2 2017

Acne Vulgaris – Pipeline by Photocure ASA, H2 2017

Acne Vulgaris – Pipeline by Promius Pharma LLC, H2 2017

Acne Vulgaris – Pipeline by Provectus Biopharmaceuticals Inc, H2 2017

Acne Vulgaris – Pipeline by Realm Therapeutics Plc, H2 2017

Acne Vulgaris – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017

Acne Vulgaris – Pipeline by Sol-Gel Technologies Ltd, H2 2017

Acne Vulgaris – Pipeline by Sun Pharmaceutical Industries Ltd, H2 2017

Acne Vulgaris – Pipeline by Taro Pharmaceutical Industries Ltd, H2 2017

Acne Vulgaris – Pipeline by Thesan Pharmaceuticals Inc, H2 2017

Acne Vulgaris – Pipeline by Valeant Pharmaceuticals International Inc, H2 2017

Acne Vulgaris – Pipeline by Vyome Biosciences Pvt Ltd, H2 2017

Acne Vulgaris – Pipeline by XBiotech Inc, H2 2017

Acne Vulgaris – Dormant Projects, H2 2017

Acne Vulgaris – Dormant Projects, H2 2017 (Contd..1), H2 2017

Acne Vulgaris – Dormant Projects, H2 2017 (Contd..2), H2 2017

Acne Vulgaris – Dormant Projects, H2 2017 (Contd..3), H2 2017

Acne Vulgaris – Dormant Projects, H2 2017 (Contd..4), H2 2017

Acne Vulgaris – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Acne Vulgaris, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports